Project Grant F30CA294723
Award Date
12/1/24
Completion Date
7/31/28
Dollars Obligated
$107K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This $530,015 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by the Fred Hutchinson Cancer Center in Seattle, WA to define how natural killer (NK) cells regulate the tumor microenvironment and enhance anti-tumor immune responses. The research aims to: Determine tumor-intrinsic features that regulate NK cell phenotype and function in the tumor; Define the mechanisms that regulate NK cell production of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $105,189 to the Regents of the University of Minnesota to advance research on inhibiting the structural dynamics of the APOBEC3A (A3A) and APOBEC3B (A3B) enzymes. The key objectives are to: Elucidate the structures of A3A and A3B when bound to viral inhibitors, such as ribonucleotide reductases from Macacine G-herpesvirus 11 and Kaposi Sarcoma-associated Herpesvirus, using...
This $130,350 Project Grant, awarded by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research to transform the discovery process for Trispecific Killer Cell Engagers (TRIKEs), a promising immunotherapy that leverages Natural Killer (NK) cells to kill tumor cells. The project aims to investigate the impact of tumor binding domain properties on TRIKE functionality and developability, including evaluating different binder scaffolds such as...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) is supporting research to investigate the therapeutic potential of "bystander" T cells in solid tumors. The $113,937 award to the Regents of the University of Minnesota will fund experiments to: 1) identify mechanisms of bystander T cell activation and cytotoxicity that can be leveraged for tumor killing, 2) overcome tumor-intrinsic regulatory pathways that inhibit bystander T...
The National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health, awarded a $101,340 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Michigan. The award will fund research to investigate the role of the MS4A14 protein in regulating macrophage activation and antigen presentation, with the goal of improving immunotherapy response in cancer patients. The research...
This Project Grant award, valued at $109,386 and provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Georgetown University focused on promoting the accumulation of activated natural killer (NK) cells in pancreatic ductal adenocarcinoma (PDAC). The research aims to investigate strategies for increasing the co-localization of activated NK cells with tumor cells in the PDAC tumor microenvironment, which the grantee's prior...
This Project Grant award of $153,348, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research by The Trustees of Columbia University in the City of New York to dissect the impact of genomic variants on T cell anti-tumor activity. The project aims to define the mechanisms by which PI3K pathway variants modulate T cell function and evaluate their in vivo efficacy in immunotherapy models for melanoma and leukemia, including in...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why TCR-T cells form a different reservoir of stem-like progenitor cells in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $217,863 to the University of Colorado-Denver to compare natural killer (NK) cell profiles within melanoma tumors and during pregnancy. The objectives are to: 1) identify biomarkers that can predict risk of disease progression and response to immune checkpoint blockade (ICB) therapy for melanoma patients, and 2) define new therapeutic targets to limit disease progression or improve...
This $312,892 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s and their secretion of interleukin-17 (IL-17) can create an immunosuppressive environment that hinders the effectiveness of immune checkpoint inhibitor (ICI) therapy for...